ScholarIQanswers from OpenAlex
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
PaperCitations, authors & open-access status
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma have?
ScholarIQcitation count
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma has 1,924 citations in the OpenAlex counts ScholarIQ stores.
When was Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma published?
ScholarIQyear
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma has 2013 year in the ScholarIQ index.
What is the open-access status of Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma?
ScholarIQoa status
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma?
ScholarIQdoi
The DOI for Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma is on the source record.
What is the PMID of Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma?
ScholarIQpmid
The PMID for Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma is on the source record.
What is the OpenAlex record for Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma?
ScholarIQopenalex
The OpenAlex for Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma is on the source record.